Maravai Lifesciences Holdings (MRVI) Stock Price & Analysis
MRVI Stock Chart & Stats
- Day’s Range
- MXN 135.00 - MXN 135.00
- 52-Week Range
- MXN 85.00 - MXN 135.00
- Previous Close
- MXN 135.00
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- MXN 38.10B
- Enterprise Value
- MXN 1.18B
- Total Cash (Recent Filing)
- MXN 70.09M
- Total Debt (Recent Filing)
- MXN 176.70M
- Price to Earnings (P/E)
- ―
- Beta
- 0.13
- Next Earnings
- Nov 04, 2026 (Est.)
- EPS Estimate
- -1.05
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Improving Growth And Margins
The combination of guided revenue growth, a substantially higher adjusted EBITDA outlook, and expected gross-margin expansion indicates meaningful operating improvement. If execution continues, better mix and efficiency could strengthen earnings capacity over the next several quarters.
Stronger Balance Sheet
Lower borrowings and extended maturities improve financial flexibility and reduce near-term refinancing pressure. The stronger liquidity position gives Maravai more capacity to support commercial initiatives and manage uneven order timing while operating performance improves.
Growing Customer And Product Adoption
Customer additions and adoption of newer technologies support a broader commercial base and demonstrate demand beyond a single program. Continued use of discovery mRNA and ModTail can deepen customer relationships and create repeat opportunities across development workflows.
Bears Say
Persistent GAAP Losses
Despite improving adjusted measures, Maravai remains materially unprofitable on a GAAP basis. Persistent losses reduce internal capital generation and show that recent revenue and margin improvements have not yet translated into a stable earnings profile.
Negative Cash Generation
Recent cash burn increases reliance on existing liquidity or external funding if it persists. Negative operating and free cash flow also limits the company’s ability to self-finance investments, absorb execution setbacks, or reduce debt rapidly.
Lumpy Program-Driven Demand
Order timing can make quarterly revenue and capacity utilization uneven, limiting visibility even while the annual outlook is maintained. The small, variable CDMO business and dependence on program-driven GMP orders may delay commercial conversion and create periods of weaker contribution.
Maravai Lifesciences Holdings News
MRVI FAQ
What was Maravai Lifesciences Holdings’s price range in the past 12 months?
What is Maravai Lifesciences Holdings’s market cap?
When is Maravai Lifesciences Holdings’s upcoming earnings report date?
How were Maravai Lifesciences Holdings’s earnings last quarter?
Is Maravai Lifesciences Holdings overvalued?
Does Maravai Lifesciences Holdings pay dividends?
What is Maravai Lifesciences Holdings’s EPS estimate?
How many shares outstanding does Maravai Lifesciences Holdings have?
What happened to Maravai Lifesciences Holdings’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Maravai Lifesciences Holdings?
What is the TipRanks Smart Score and how is it calculated?
Maravai Lifesciences Holdings Stock Smart Score
Company Description
Maravai Lifesciences Holdings
Maravai LifeSciences Holdings, Inc. is a life sciences company operating globally, supplying essential products that facilitate the advancement of drug therapies, diagnostics, innovative vaccines, and research into human diseases. Its diverse product line supports critical stages of biopharmaceutical development, featuring nucleic acids for both diagnostic and therapeutic applications, antibody-based solutions for detecting impurities in biopharmaceutical manufacturing, and tools for monitoring protein expression across different tissue types. The company conducts its operations through two distinct segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment specializes in manufacturing and distributing products integral to gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics. This encompasses reagents utilized in the chemical synthesis, modification, labeling, and purification of DNA and RNA. Additionally, this division provides messenger RNA, oligonucleotides, their foundational building blocks, plasmid DNA, and the proprietary CleanCap capping technology. Meanwhile, the Biologics Safety Testing segment offers analytical products vital for developing biologic manufacturing processes. Its offerings include bespoke antibody and assay development services tailored to specific products, alongside HCP ELISA kits, various other ELISA kits for identifying bioprocess impurities and contaminants, ancillary reagents, and custom service solutions. Maravai's clientele spans biopharmaceutical companies, other life sciences and biopharmaceutical research firms, academic research institutions, and in vitro diagnostics companies. Incorporated in 2020, Maravai LifeSciences Holdings, Inc. maintains its headquarters in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Bernd Brust
- Employees
- 415
- Website
- www.maravai.com
- Address
- 10770 Wateridge Circle, San Diego, CA, 92121, US
Maravai Lifesciences Holdings (MRVI) Earnings & Revenues
MRVI Company Deck
MRVI Earnings Call
Earnings Call SentimentPositive
The earnings call conveyed strong operational progress and financial improvement: revenue growth, large margin expansion, significantly improved adjusted EBITDA, record customer additions, product launches and patent wins, plus a materially strengthened balance sheet via refinancing. The primary negatives are that GAAP losses persist, certain businesses (CDMO and some new products) remain lumpy or early-stage, and timing risk exists around large program-driven orders and GMP conversions. On balance, the call emphasized accelerating commercial execution and durable margin improvement, with management maintaining prudent revenue guidance while raising confidence in profitability.
View all MX:MRVI earnings summariesMRVI Net sales Breakdown
- 77.79% Nucleic Acid Production
- 22.21% Biologics Safety Testing
MRVI Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 13 | 4 | 0 |
| Technical Analysis | 3 | 2 | 0 |
| Moving Averages | 10 | 2 | 0 |